BioNTech Results Presentation Deck
BNT162: Global commercial supply commitments*
ā
9
> 570 million doses committed* for
2020 and 2021 in 13 countries and the
EU with an option to purchase an
additional 600 million doses
Additional commercial discussions
ongoing with multiple countries and
supranational organizations including
COVAX
* Subject to clinical success and regulatory approval
Region
Canada
EU
Commercial supply commitments*
Number of Doses
Not disclosed
200 million with
option for additional
100 million
120 million
30 million
100 million with option
for additional
500 million
Japan
United Kingdom
United States
Nine additional
countries
Not disclosed
Order value
Not disclosed
Not disclosed
Not disclosed
Not disclosed
$1.95 billion for first
100 million doses
Not disclosed
BIONTECHView entire presentation